Blastic plasmacytoid dendritic cell neoplasm
Blastic Plasmacytoid Dendritic Cell Neoplasm
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy characterized by the proliferation of plasmacytoid dendritic cells. It primarily affects the skin, bone marrow, and lymph nodes.
Clinical Presentation[edit | edit source]
Patients with BPDCN often present with skin lesions, which may appear as bruise-like patches, nodules, or plaques. These lesions are typically purple or red and can occur anywhere on the body. In addition to skin involvement, BPDCN can affect the bone marrow, leading to cytopenias, and the lymph nodes, causing lymphadenopathy.
Pathophysiology[edit | edit source]
BPDCN arises from plasmacytoid dendritic cells, which are a type of immune cell involved in the production of interferon and the activation of other immune cells. The neoplastic cells in BPDCN express markers such as CD4, CD56, and CD123, which are used in the diagnosis of the disease.
Diagnosis[edit | edit source]
The diagnosis of BPDCN is based on a combination of clinical presentation, histopathological examination, and immunophenotyping. Skin biopsies, bone marrow aspirates, and lymph node biopsies are commonly used to obtain tissue samples for analysis. Immunohistochemistry is employed to detect the characteristic markers of BPDCN.
Treatment[edit | edit source]
Treatment options for BPDCN include chemotherapy, targeted therapy, and hematopoietic stem cell transplantation. Traditional chemotherapy regimens used for acute leukemia may be employed, but newer targeted therapies, such as tagraxofusp, have shown promise in treating BPDCN. Allogeneic stem cell transplantation is considered in eligible patients to achieve long-term remission.
Prognosis[edit | edit source]
The prognosis for BPDCN is generally poor due to its aggressive nature and high rate of relapse. Early diagnosis and treatment are crucial for improving outcomes. The development of targeted therapies has provided new hope for patients with this challenging disease.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
